Latest news with #MichaelDavidson
Yahoo
a day ago
- Business
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Yahoo
a day ago
- Business
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Sunday World
30-05-2025
- Sunday World
Man acted like ‘bull in a china shop' when he grabbed garda and threatened to choke him
Michael Davidson, Meeting House Lane, Linenhall Street, Dundalk, had been walking along the centre of the road in front of a Garda patrol vehicle before the incident occurred. A 43-year-old man grabbed a Garda by the lapels, forced him against a wall and threatened to choke him, Dundalk Court has heard. Michael Davidson, Meeting House Lane, Linenhall Street, Dundalk, had been walking along the centre of the road in front of a Garda patrol vehicle before the incident occurred. He pleaded guilty to being intoxicated in public, using or engaging in threatening, abusive or insulting behaviour or words, obstructing a Garda in the execution of his duty and a Section 35 pedestrian offence at Quay Street, Dundalk, on December 7, 2023. Dundalk Court. Stock image. News in 90 Seconds - May 30th Evidence was given that the defendant was walking in the centre of the road ahead of a patrol vehicle. He stopped and began shouting at it. Mr Davidson refused to move on several occasions before the Garda drove around him, pulled in and got out. The man again refused to move. He was shouting aggressively at the officer and, while being escorted, grabbed him by the lapels and forced him against a wall. He attempted to strike the Garda and said that he would choke him. He referred to 'a previous attack he carried out with a bottle'. There were 51 previous convictions. Barrister Niall Mackin said that the defendant was on medication and had addiction issues at the time. He completed a Turas Counselling Service course and was clean since. Mr Davidson had one child, one grandchild and was carer for his partner. He instructed that he would not be in trouble again. He had €300 to offer. Judge Nicola Andrews said she wouldn't let a situation pass with a charitable donation when a Garda was attacked. The defendant 'was like a bull in a china shop,' the judge added. He was remanded on continuing bail to June 11 for a probation report and community service assessment. Funded by the Courts Reporting Scheme
Yahoo
29-05-2025
- Business
- Yahoo
California could nearly double generation capacity using surplus interconnection: Berkeley report
This story was originally published on Utility Dive. To receive daily news and insights, subscribe to our free daily Utility Dive newsletter. California could accelerate the deployment of clean energy and save billions of dollars by adding more generation and storage at underutilized interconnections for existing power plants, according to a working paper by researchers at the University of California, Berkeley. The Federal Energy Regulatory Commission opened the door for new sources to use surplus interconnection with Order 845 in 2018. Several experts said the research was promising, but the California Independent System Operator said the report likely 'significantly overstates' commercial interest and feasibility. Like many states, California is facing a congested interconnection queue, costly transmission upgrades and rising retail electricity rates. The Berkeley paper, which has not been peer-reviewed, claims to have analyzed hundreds of existing renewable and thermal plants in California and identified potential for 53 GW of additional clean energy capacity, including wind and solar, as well as 23 GW of storage, through surplus interconnection. In total, it says that adding 76 GW of clean energy capacity could nearly double the state's installed generation capacity, which was 89 GW in 2024, according to the California Energy Commission. The report was published earlier this month along with an interactive map of surplus interconnection. The paper concludes that, in general, both renewable and fossil fuel generators underutilize their interconnections, but this is especially true of gas-powered peaker plants. Overall, the paper says about 16 GW of fossil fuel capacity is operating only 15% of the time or less. 'So for 85% of the time, the connection where that gas plant is sending electricity to the grid is essentially idle,' said Umed Paliwal, one of the report's authors and a senior scientist at Berkeley's Goldman School of Public Policy. 'What if you could add solar and wind near these underutilized interconnections? … This is a very fast way to bring capacity online.' In an emailed response to questions, a spokesperson for CAISO said the grid operator currently has 230 GW of resources in its interconnection queue, and has 'awarded deliverability' to about 60 GW. They said a surplus interconnection service pathway is already available under the ISO tariff, however, 'we have not seen significant interest in this approach from developers.' Michael Davidson, an assistant professor at UC San Diego's School of Global Policy and Strategy and the Jacobs School of Engineering, called the report 'interesting,' but added that he would like to see more details of its methodology. 'I believe the authors propose a creative solution to partially addressing the interconnection bottleneck,' he wrote in an email. However, he continued, one cannot make a straightforward comparison between gas plants and renewables in terms of levelized costs. 'If a gas peaker plant is only operating 1% of the year, it is because those are the hours in which prices are high enough to justify operation,' Davidson said. 'In addition to capacity factor utilization, future analyses should examine how much the existing thermal plants are utilizing the interconnection during peak periods, and therefore how much additional supply can be put on the grid when it is needed most.' Mark Jacobson, a professor of civil and environmental engineering at Stanford, wrote in an email that the paper's results are 'credible in principle, although it is hard to confirm the exact numbers.' 'There is bound to be low-hanging fruit' in terms of adding wind, solar and storage to existing interconnection sites, he said. Recommended Reading California targets up to 2 GW of long-duration storage as part of 10.6 GW clean energy procurement
